Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.

Li Y, Lupo JM, Polley MY, Crane JC, Bian W, Cha S, Chang S, Nelson SJ.

Neuro Oncol. 2011 May;13(5):546-57. doi: 10.1093/neuonc/noq194.

2.

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.

Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ.

J Neurooncol. 2015 Jan;121(2):331-9. doi: 10.1007/s11060-014-1636-6.

3.

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ.

J Neurooncol. 2009 Jan;91(1):69-81. doi: 10.1007/s11060-008-9685-3.

4.

Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma.

Akgoz A, Rahman R, You H, Qu J, Hamdan A, Seethamraju RT, Wen PY, Young GS.

J Neurooncol. 2014 Aug;119(1):111-9. doi: 10.1007/s11060-014-1454-x.

PMID:
24792644
5.

Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.

Elson A, Bovi J, Siker M, Schultz C, Paulson E.

J Neurooncol. 2015 May;122(3):549-58. doi: 10.1007/s11060-015-1743-z.

PMID:
25700835
6.
7.

Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.

Li Y, Lupo JM, Parvataneni R, Lamborn KR, Cha S, Chang SM, Nelson SJ.

Neuro Oncol. 2013 May;15(5):607-17. doi: 10.1093/neuonc/nos334.

8.

Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

Bag AK, Cezayirli PC, Davenport JJ, Gaddikeri S, Fathallah-Shaykh HM, Cantor A, Han XS, Nabors LB.

J Neurooncol. 2014 Nov;120(2):361-70. doi: 10.1007/s11060-014-1560-9.

9.
10.

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.

Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY.

J Neurooncol. 2014 Aug;119(1):149-58. doi: 10.1007/s11060-014-1464-8.

PMID:
24805151
11.

Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.

Lee EK, Choi SH, Yun TJ, Kang KM, Kim TM, Lee SH, Park CK, Park SH, Kim IH.

Korean J Radiol. 2015 Nov-Dec;16(6):1341-8. doi: 10.3348/kjr.2015.16.6.1341.

12.

Evaluation of early imaging response criteria in glioblastoma multiforme.

Gladwish A, Koh ES, Hoisak J, Lockwood G, Millar BA, Mason W, Yu E, Laperriere NJ, Ménard C.

Radiat Oncol. 2011 Sep 23;6:121. doi: 10.1186/1748-717X-6-121.

13.

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ.

J Neurooncol. 2009 Feb;91(3):337-51. doi: 10.1007/s11060-008-9719-x.

14.

Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Ken S, Deviers A, Filleron T, Catalaa I, Lotterie JA, Khalifa J, Lubrano V, Berry I, Péran P, Celsis P, Moyal EC, Laprie A.

J Neurooncol. 2015 Sep;124(3):465-73. doi: 10.1007/s11060-015-1860-8.

PMID:
26189058
15.
16.

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.

Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A.

Neuro Oncol. 2015 Aug;17(8):1139-47. doi: 10.1093/neuonc/nov028.

17.

Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?

Nakamura H, Murakami R, Hirai T, Kitajima M, Yamashita Y.

Acta Radiol. 2013 Mar 1;54(2):214-20. doi: 10.1258/ar.2012.120525.

PMID:
23138021
18.

Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.

Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ.

Neuro Oncol. 2013 Apr;15(4):480-9. doi: 10.1093/neuonc/nos325.

19.

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.

Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T.

J Neurooncol. 2012 Jul;108(3):491-8. doi: 10.1007/s11060-012-0847-y.

20.

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.

Romano A, Calabria LF, Tavanti F, Minniti G, Rossi-Espagnet MC, Coppola V, Pugliese S, Guida D, Francione G, Colonnese C, Fantozzi LM, Bozzao A.

Eur Radiol. 2013 Feb;23(2):513-20. doi: 10.1007/s00330-012-2601-4.

PMID:
22875158
Items per page

Supplemental Content

Support Center